What is King Pharmaceuticals's G&A?

King Pharmaceuticals (KG) reported G&A of $11.74M in Q1 2026.

How has King Pharmaceuticals's G&A changed year-over-year?

King Pharmaceuticals's G&A increased by 927.4% year-over-year, from $1.14M to $11.74M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

King Pharmaceuticals KG G&A

G&A at other companies

Arch Capital GroupACGL

$49M-18.3%

Silvercrest Asset Management GroupSAMG

$9M+17.3%

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's G&A?: King Pharmaceuticals (KG) reported G&A of $11.74M in Q1 2026.
How has King Pharmaceuticals's G&A changed year-over-year?: King Pharmaceuticals's G&A increased by 927.4% year-over-year, from $1.14M to $11.74M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.